We can’t show the full text here under this license. Use the link below to read it at the source.
Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT ‐1 study
Weight loss with tirzepatide linked to better quality of life in adults with obesity
AI simplified
Abstract
Participants achieving ≥20% weight reduction showed significant improvements in measures.
- All tirzepatide treatment groups experienced significant enhancements in compared to placebo.
- Incremental improvements in quality of life measures were observed with greater degrees of weight reduction, starting from ≥5%.
- Participants with ≥20% weight reduction had the largest increases in scores for physical and mental health components.
- Individuals with baseline physical and psychosocial limitations reported greater improvements in health-related quality of life than those without such limitations.
AI simplified
Key numbers
24.7
IWQOL-Lite-CT Total Score Change
Change from baseline to week 72 in tirzepatide-treated participants.
4.60
SF-36v2 Physical Component Summary Change
Change from baseline to week 72 in tirzepatide-treated participants.
0.80
SF-36v2 Mental Component Summary Change
Change from baseline to week 72 in tirzepatide-treated participants.